Compare UNB & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | FATE |
|---|---|---|
| Founded | 1891 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 125.6M |
| IPO Year | 1999 | 2013 |
| Metric | UNB | FATE |
|---|---|---|
| Price | $23.04 | $2.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $5.74 |
| AVG Volume (30 Days) | 2.2K | ★ 1.3M |
| Earning Date | 10-21-2026 | 11-12-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | 25.52 | ★ 29.88 |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.65 | $0.95 |
| 52 Week High | $26.41 | $3.23 |
| Indicator | UNB | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 46.42 |
| Support Level | $22.89 | $1.81 |
| Resistance Level | $24.16 | $2.60 |
| Average True Range (ATR) | 0.36 | 0.14 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 33.99 | 49.32 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.